1. Home
  2. NBIX vs CACI Comparison

NBIX vs CACI Comparison

Compare NBIX & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBIX
  • CACI
  • Stock Information
  • Founded
  • NBIX 1992
  • CACI 1962
  • Country
  • NBIX United States
  • CACI United States
  • Employees
  • NBIX N/A
  • CACI N/A
  • Industry
  • NBIX Biotechnology: Biological Products (No Diagnostic Substances)
  • CACI EDP Services
  • Sector
  • NBIX Health Care
  • CACI Technology
  • Exchange
  • NBIX Nasdaq
  • CACI Nasdaq
  • Market Cap
  • NBIX 12.2B
  • CACI 9.7B
  • IPO Year
  • NBIX 1996
  • CACI 1979
  • Fundamental
  • Price
  • NBIX $128.00
  • CACI $481.77
  • Analyst Decision
  • NBIX Strong Buy
  • CACI Strong Buy
  • Analyst Count
  • NBIX 20
  • CACI 14
  • Target Price
  • NBIX $163.20
  • CACI $508.46
  • AVG Volume (30 Days)
  • NBIX 879.2K
  • CACI 256.2K
  • Earning Date
  • NBIX 07-31-2025
  • CACI 08-06-2025
  • Dividend Yield
  • NBIX N/A
  • CACI N/A
  • EPS Growth
  • NBIX N/A
  • CACI 22.32
  • EPS
  • NBIX 2.96
  • CACI 21.19
  • Revenue
  • NBIX $2,412,600,000.00
  • CACI $8,361,975,000.00
  • Revenue This Year
  • NBIX $16.29
  • CACI $14.60
  • Revenue Next Year
  • NBIX $15.08
  • CACI $7.33
  • P/E Ratio
  • NBIX $42.50
  • CACI $22.83
  • Revenue Growth
  • NBIX 21.73
  • CACI 14.16
  • 52 Week Low
  • NBIX $84.23
  • CACI $318.60
  • 52 Week High
  • NBIX $157.98
  • CACI $588.26
  • Technical
  • Relative Strength Index (RSI)
  • NBIX 62.53
  • CACI 64.92
  • Support Level
  • NBIX $125.02
  • CACI $454.44
  • Resistance Level
  • NBIX $128.66
  • CACI $469.13
  • Average True Range (ATR)
  • NBIX 2.68
  • CACI 11.60
  • MACD
  • NBIX -0.34
  • CACI 3.17
  • Stochastic Oscillator
  • NBIX 80.79
  • CACI 98.73

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

Share on Social Networks: